Introduction : Les complications de l’infection par le SARS-CoV-2 peuvent affecter la sphère neurologique ; il s’agit habituellement de cas de polyradiculonévrite aiguë inflammatoire ou de plexite. Observation : Le cas clinique rapporté concerne un patient de 20 ans sans comorbidités, atteint d’une infection sévère à la COVID-19 compliquée d’un Syndrome de Détresse Respiratoire Aigüe, avec manifestations thromboemboliques et surinfection bactérienne. Ce patient souffrait également d'un trouble neurologique non spécifique lié au SARS-Cov-2 avec une paralysie pseudobulbaire (IRM, ENMG et ponction lombaire étaient normaux), associé à des troubles neurologiques persistants 4 mois plus tard, caractérisés par un déficit à prédominance motrice de l'épaule gauche et une insuffisance respiratoire. Le bilan respiratoire et neurologique conclut à un syndrome de Parsonage-Turner, ou amyotrophie névralgique, affectant les racines nerveuses en C5-C6, le nerf pectoral latéral et le nerf phrénique à l'origine de l'amyotrophie de la ceinture scapulaire et de la paralysie du diaphragme gauche. Conclusion : Ce cas montre que la dyspnée persistante après une infection à la COVID-19 doit faire rechercher une cause diaphragmatique et que celle-ci n’est pas toujours secondaire à la neuropathie de réanimation, mais peut aussi être le témoin d’une amyotrophie névralgique.
Introduction: Given the pathophysiology of coronavirus disease 19 (COVID-19), persistent pulmonary abnormalities are likely. Methods:We conducted a prospective cohort study in severe COVID-19 patients who had oxygen saturation <94% and were primarily admitted to hospital. We aimed to describe persistent gas exchange abnormalities at 4 months, defined as decreased diffusing capacity of the lungs for carbon monoxide (DLco) and/or desaturation on the 6-minute walk test (6MWT), along with associated mechanisms and risk factors Results: Of the 72 patients included, 76.1% required admission to the intensive care unit (ICU), while 68.5% required invasive mechanical ventilation (MV). 39.1% developed venous thromboembolism (VTE). At 4 months, 61.4% were still symptomatic. Functionally, 39.1% had abnormal carbon monoxide test results and/or desaturation on 6MWT; high-flow oxygen, MV, and VTE during the acute phase were significantly associated. Restrictive lung disease was observed in 23.6% of cases, obstructive lung disease in 16.7%, and respiratory muscle dysfunction in 18.1%. A severe initial presentation with admission to ICU (p=.0181), and VTE occurrence during the acute phase (p=.0089) were associated with these abnormalities. 41% had interstitial lung disease in computed tomography (CT) of the chest. Four patients (5.5%) displayed residual defects on lung scintigraphy, only one of whom had developed VTE during the acute phase (5.5%). The main functional respiratory abnormality (31.9%) was reduced capillary volume (Vc<70%). Conclusion: Among patients with severe COVID-19 pneumonia who were admitted to hospital, 61% were still symptomatic, 39% of patients had persistent functional abnormalities and 41% radiological abnormalities after 4 months. Embolic sequelae were rare but the main functional respiratory abnormality was reduced capillary volume. A respiratory check-up after severe COVID-19 pneumonia may be relevant to improve future management of these patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.